Selective Serotonin Reuptake Inhibitors
Authors:
- 1 January 2018
- book chapter
- Published by Springer Nature
- Vol. 250, 135-144
Abstract
The first antidepressants were created by chance but brought the idea that central serotonin agonism produced an antidepressant effect. SSRIs were the first class of psychotropic medications to be rationally designed, meaning that researchers intended to utilize a specific mechanism of action while avoiding adverse effects. In this way, SSRIs were created to be safer and more tolerable than previous antidepressants. SSRIs share many similarities, but differ in terms of pharmacokinetics and effects on CYP450 enzymes, which is detailed in this chapter. Further information will be provided regarding safety, clinical indications/uses, and dosing recommendations.Keywords
This publication has 10 references indexed in Scilit:
- A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetineExpert Opinion on Pharmacotherapy, 2014
- Selective Serotonin Reuptake Inhibitors2004
- Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamideClinical Pharmacology & Therapeutics, 2001
- Birth Outcomes in Pregnant Women Taking FluoxetineNew England Journal of Medicine, 1996
- Cytochrome P450 EnzymesJournal of Clinical Psychopharmacology, 1996
- Cytochrome P450 EnzymesJournal of Clinical Psychopharmacology, 1996
- Effects of Third Trimester Fluoxetine Exposure on the NewbornJournal of Clinical Psychopharmacology, 1995
- Should rational drug development in psychiatry target more than one mechanism of action in a single molecule?International Review of Psychiatry, 1995
- Sertraline in the Prevention of DepressionThe British Journal of Psychiatry, 1992
- The Future and Psychopharmacology: Potentials and NeedsPsychiatric Annals, 1990